Literature DB >> 8593031

In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.

T Nakane1, S Iyobe, K Sato, S Mitsuhashi.   

Abstract

The in vitro antibacterial activity of DU-6859a, a new fluoroquinolone, against a wide variety of clinical isolates was evaluated and compared with those of tosufloxacin, ofloxacin, ciprofloxacin, and sparfloxacin. DU-6859a showed potent broad-spectrum activity against gram-positive, gram-negative, and anaerobic bacteria, and its activity was greater than those of the control quinolones. By comparison of MICs at which 90% of strains are inhibited, DU-6859a had potent activity against bacteria resistant to the control quinolones. The time-killing curves of quinolones showed that the number of viable cells decreased rapidly during 2 to 4 of incubation, and regrowth was not seen even after 8 h incubation. At a concentration of four times the MIC, the frequencies of appearance of spontaneous mutants of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa resistant to DU-6859a were < or = 4.0 x 10(-9) to 1.9 x 10(-8). The 50% inhibitory concentrations of DU-6859a were 0.86 and 1.05 micrograms/ml for the supercoiling activities of DNA gyrases isolated from E. coli and P. aeruginosa, respectively. The rank order of the 50% inhibitory concentrations observed for both DNA gyrases roughly paralleled the MICs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593031      PMCID: PMC163041          DOI: 10.1128/AAC.39.12.2822

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

2.  Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant.

Authors:  Y Inoue; K Sato; T Fujii; K Hirai; M Inoue; S Iyobe; S Mitsuhashi
Journal:  J Bacteriol       Date:  1987-05       Impact factor: 3.490

3.  Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.

Authors:  K Sato; Y Inoue; T Fujii; H Aoyama; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.

Authors:  K Fujimaki; T Noumi; I Saikawa; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

5.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

6.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

7.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

  9 in total
  9 in total

1.  Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.

Authors:  T Akasaka; S Kurosaka; Y Uchida; M Tanaka; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 3.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 4.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  J Turnidge
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.

Authors:  D Milatovic; F J Schmitz; S Brisse; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.

Authors:  T Akasaka; Y Onodera; M Tanaka; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

8.  In vitro and in vivo activities of sitafloxacin against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.

Authors:  Frederick A Browne; Bülent Bozdogan; Catherine Clark; Linda M Kelly; Lois Ednie; Klaudia Kosowska; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.